Advanced Ophthalmic Pharma

Advanced Ophthalmic Pharma Ltd., established in 2007, is a biomedical company focused on the development of technologies within the ophthalmology sector. The enterprise was founded by Dr. Eran Eilat, who also served as its Chief Executive Officer. Situated in Tel Aviv, Israel, the company directs its efforts towards creating novel solutions for eye care.

Operationally, the company functions within the medical device and pharmaceutical market, specifically targeting ophthalmic applications. Its business model centers on the research and development of drug delivery systems. In a significant milestone, Advanced Ophthalmic Pharma secured $2 million in a funding round in 2010, backed by a group of investors including Coronis Partners, which specializes in Israeli biomed investments. This capital was intended to advance the company's technology and support its growth in a market valued at over $13 billion annually at the time.

The company's principal product is the Eye AdMister, a proprietary drug delivery device. This system is engineered to administer preservative-free ophthalmic drug formulations as a fine mist. The design aims to deliver precise doses of medication and achieve a high level of absorption, addressing common challenges in topical eye treatments.

Keywords: ophthalmic technology, drug delivery system, Eye AdMister, biomedical devices, eye care solutions, preservative-free formulations, mist application, ophthalmic drugs, ocular medicine, Israeli biomed, ophthalmic surgical, vision care, retinal disease therapy, glaucoma treatment, ocular health